ArticleInfection and drug resistance2026
Nintedanib Enhances the Antibacterial Activity of Bedaquiline Against Non-Tuberculous Mycobacteria: In vitro and in Mice Models.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Non-tuberculous mycobacteria (NTM) are ubiquitous in the natural environment. Globally, incidence of non-tuberculous mycobacterial disease is on the rise. To date, over 190 species of NTM have been identified, many of which possess inherent natural resistance to antibiotics, developing new drugs is a challenging process with a high risk of failure. The repurposing of existing drugs may be a quick and effective approach. This study investigates the combined effects of bedaquiline (BDQ) and nintedanib (a multi-target tyrosine kinase inhibitor) on NTM, with the aim of providing a novel therapeutic approach against NTM. Methods and Results: The number of colony-forming units (CFUs) in macrophages was determined to assess the antibacterial activity of nintedanib against Conclusion: In vitro and in vivo studies have shown that nintedanib enhances the antibacterial activity of BDQ, accelerates pathogen clearance and reduces lung damage. Nintedanib adjuvant therapy modulates the body's adaptive immune response, promoting resolution of inflammation and tissue repair. Nintedanib may enhance the efficacy of BDQ by interfering with bacterial ATP synthesis and metabolic pathways. These findings highlight the potential of BDQ combined with nintedanib for the treatment of NTM infections and provide a crucial theoretical basis for the development of more effective therapeutic strategies for NTM infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.